US Market for Soft Tissue Reinforcement and Regeneration 2014 (Forecasted to 2020) - MedSuite
|発行||iData Research Inc.||商品コード||315013|
|出版日||ページ情報||英文 225 Pages
|米国の軟部組織補強および再生市場 US Market for Soft Tissue Reinforcement and Regeneration 2014 (Forecasted to 2020) - MedSuite|
|出版日: 2014年10月01日||ページ情報: 英文 225 Pages||
The U.S. soft tissue reinforcement and regeneration market consists of specialized grafting devices utilized for the surgical treatment of a broad range of indications. While synthetic alloplast products have been traditionally used, newer biologic products have been gaining traction in this market. These new products offer superior regenerative results by expediting the healing process and reducing the likelihood of further post-operative complications.
Biologic products have a significantly higher cost, but in most cases, the added benefits they offer outweigh their premium prices. The increasing unit sales of these specialized biologic products combined with their substantially higher ASP will fuel strong growth in the overall market.
The breast reconstruction market will more than double in value over the forecast period. Exceptionally strong double-digit growth will be driven by increases in unit sales volumes. The breast reconstruction market will more than double in value over the forecast period. Exceptionally strong double-digit growth will be driven by increases in unit sales volumes.
The incidence of breast cancer in younger women has been increasing in the United States; this population is more likely to opt for both mastectomy and breast reconstruction. The vast majority of breast reconstructions were tissue expander/implant-based (TEI) reconstructions. The remaining procedures were performed with autologous tissue, using techniques such as latissimus dorsi myocutaneous (LDM) flap, deep inferior epigastric perforators (DIEP) flap and transverse rectus abdominis myocutaneous (TRAM) flap.
In the last few decades, there has been an ongoing trend in the U.S. for women to undergo a prophylactic double mastectomy for preventative measures, even if breast cancer was only diagnosed in one breast. If the patient then decides to undergo breast reconstruction, both breasts must be completely rebuilt. This has caused the rate of bilateral reconstructions to skyrocket and has dramatically impacted the growth of the breast reconstruction market, as one product is usually used for each breast during a reconstructive procedure.